Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas (pages 3330–3336)
Antoine Italiano, Angela Cioffi, Nicolas Penel, Matteo Giaj Levra, Corinne Delcambre, Elsa Kalbacher, Christine Chevreau, François Bertucci, Nicolas Isambert, Jean-Yves Blay, Binh Bui, Cristina Antonescu, David R. D'Adamo, Robert G. Maki and Mary Louise Keohan
Article first published online: 1 NOV 2011 | DOI: 10.1002/cncr.26599
Single-agent doxorubicin is still considered the first-line standard treatment for patients with metastatic soft-tissue sarcoma (STS). However, several studies have shown that paclitaxel, a drug considered inactive against STS, has significant activity in angiosarcomas, particularly when administered in a weekly schedule. The results of this study show that angiosarcomas are at least initially chemosensitive, and indicate that doxorubicin and weekly paclitaxel appear largely equivalent in terms of efficacy in the first-line setting.